228 related articles for article (PubMed ID: 32639460)
41. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
Madhi SA; Mutsaerts EA; Izu A; Boyce W; Bhikha S; Ikulinda BT; Jose L; Koen A; Nana AJ; Moultrie A; Roalfe L; Hunt A; Goldblatt D; Cutland CL; Dorfman JR
Lancet Infect Dis; 2020 Dec; 20(12):1426-1436. PubMed ID: 32857992
[TBL] [Abstract][Full Text] [Related]
42. Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.
Wijmenga-Monsuur AJ; van Westen E; Knol MJ; Jongerius RM; Zancolli M; Goldblatt D; van Gageldonk PG; Tcherniaeva I; Berbers GA; Rots NY
PLoS One; 2015; 10(12):e0144739. PubMed ID: 26658902
[TBL] [Abstract][Full Text] [Related]
43. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China.
Zhu F; Hu Y; Li J; Ye Q; Young MM; Liang JZ; Gruber WC; Giardina PC; Scott DA
Pediatr Infect Dis J; 2019 Nov; 38(11):1150-1158. PubMed ID: 31626050
[TBL] [Abstract][Full Text] [Related]
44. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
[TBL] [Abstract][Full Text] [Related]
45. Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).
Hammitt LL; Quinn D; Janczewska E; Pasquel FJ; Tytus R; Rajender Reddy K; Abarca K; Khaertynova IM; Dagan R; McCauley J; Cheon K; Pedley A; Sterling T; Tamms G; Musey L; Buchwald UK
Open Forum Infect Dis; 2022 Mar; 9(3):ofab605. PubMed ID: 35146039
[TBL] [Abstract][Full Text] [Related]
46. The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C.
Shi Y; Nolan KM; Burton RL; Shekar T; Murphy RD; Banniettis N; Musey L; Buchwald UK
Hum Vaccin Immunother; 2023 Aug; 19(2):2235238. PubMed ID: 37529944
[TBL] [Abstract][Full Text] [Related]
47. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
[TBL] [Abstract][Full Text] [Related]
48. A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR).
Maestri A; Park SE; Fernandes F; Li ZL; Kim YJ; Kim YK; Lee J; Park JY; Kim DH; Yang G; Lim H; Kim JO; Lupinacci R; Sterling TM; Wilck M; Esteves-Jaramillo A; Banniettis N
Hum Vaccin Immunother; 2024 Dec; 20(1):2321035. PubMed ID: 38497448
[TBL] [Abstract][Full Text] [Related]
49. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial.
Silfverdal SA; Flodmark CE; Rombo L; Tansey SP; Sidhu M; Trammel J; Emini EA; Gruber WC; Scott DA; Gurtman A;
Vaccine; 2013 Feb; 31(9):1284-92. PubMed ID: 23306363
[TBL] [Abstract][Full Text] [Related]
50. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.
Senders S; Klein NP; Lamberth E; Thompson A; Drozd J; Trammel J; Peng Y; Giardina PC; Jansen KU; Gruber WC; Scott DA; Watson W
Pediatr Infect Dis J; 2021 Oct; 40(10):944-951. PubMed ID: 34525007
[TBL] [Abstract][Full Text] [Related]
51. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.
Weckx LY; Thompson A; Berezin EN; de Faria SM; da Cunha CA; Pride M; Patterson S; Gruber WC; Emini EA; Scott DA;
Vaccine; 2012 Dec; 30(52):7566-72. PubMed ID: 23099331
[TBL] [Abstract][Full Text] [Related]
52. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.
Goldblatt D; Southern J; Andrews NJ; Burbidge P; Partington J; Roalfe L; Valente Pinto M; Thalasselis V; Plested E; Richardson H; Snape MD; Miller E
Lancet Infect Dis; 2018 Feb; 18(2):171-179. PubMed ID: 29174323
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
[TBL] [Abstract][Full Text] [Related]
54. Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.
Juergens C; Patterson S; Trammel J; Greenberg D; Givon-Lavi N; Cooper D; Gurtman A; Gruber WC; Scott DA; Dagan R
Clin Vaccine Immunol; 2014 Sep; 21(9):1277-81. PubMed ID: 24990907
[TBL] [Abstract][Full Text] [Related]
55. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to korean children receiving routine pediatric vaccines.
Kim DS; Shin SH; Lee HJ; Hong YJ; Lee SY; Choi KM; Oh CE; Kim KH; Juergens C; Patterson S; Giardina PC; Gruber WC; Emini EA; Scott DA
Pediatr Infect Dis J; 2013 Mar; 32(3):266-73. PubMed ID: 23011012
[TBL] [Abstract][Full Text] [Related]
56. Safety and Immunogenicity of V114, a 15-valent Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE).
Kishino H; Sawata M; Igarashi R; Shirakawa M; Pedley A; Musey L; Platt HL; Buchwald UK
Jpn J Infect Dis; 2022 Nov; 75(6):575-582. PubMed ID: 35908869
[TBL] [Abstract][Full Text] [Related]
57. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.
Snape MD; Klinger CL; Daniels ED; John TM; Layton H; Rollinson L; Pestridge S; Dymond S; Galiza E; Tansey S; Scott DA; Baker SA; Jones TR; Yu LM; Gruber WC; Emini EA; Faust SN; Finn A; Heath PT; Pollard AJ
Pediatr Infect Dis J; 2010 Dec; 29(12):e80-90. PubMed ID: 21155091
[TBL] [Abstract][Full Text] [Related]
58. Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes.
Grant LR; O'Brien SE; Burbidge P; Haston M; Zancolli M; Cowell L; Johnson M; Weatherholtz RC; Reid R; Santosham M; O'Brien KL; Goldblatt D
PLoS One; 2013; 8(9):e74906. PubMed ID: 24086394
[TBL] [Abstract][Full Text] [Related]
59. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA;
Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524
[TBL] [Abstract][Full Text] [Related]
60. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.
Yeh SH; Gurtman A; Hurley DC; Block SL; Schwartz RH; Patterson S; Jansen KU; Love J; Gruber WC; Emini EA; Scott DA;
Pediatrics; 2010 Sep; 126(3):e493-505. PubMed ID: 20732948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
